Monthly Archives: March 2013

Imprime PGG Modulates Adaptive Immune Responses, Indicating Broader Potential for Treating Disease

New Research Presented at Immunology Conference EAGAN, MN – March 14, 2013 – Imprime PGG®, the immunotherapeutic drug candidate that redirects innate immune cells to recognize and kill cancer, also modulates adaptive immune system functions, Biothera researchers reported recently at the Gordon Research Conference on Immunology of Fungal Infections held in Galveston, Texas. The study found that Imprime PGG binds human B cells, enhancing both...

Read More


Biothera Completes Enrollment of Second Phase 2b Lung Cancer Trial

EAGAN, MN — March 12, 2013 — Biothera announced today that it has completed enrollment of its 90-patient Phase 2b clinical study of Imprime PGG®, bevacizumab (Avastin®) and two chemotherapeutic drugs in non-small cell lung cancer (NSCLC). Imprime PGG, Biothera’s immunotherapeutic drug candidate, is being evaluated in lung and colorectal cancer, chronic lymphocytic leukemia and non-Hodgkins lymphoma. The open label, randomized Phase 2b study has...

Read More


Biothera Participates in 24th Annual Cancer Progress Conference

EAGAN, MN – March 6, 2013 – Many anti-tumor monoclonal antibodies (MAb) successfully target cancer cells but are less effective at killing tumors. An expert panel at the 24th Annual Cancer Progress Conference will discuss ways to improve MAb efficacy as well as other approaches to cancer therapy. William Grossman, M.D., Ph.D., senior vice president, Research & Development, for Biothera, will participate in the panel...

Read More


Imprime PGG Pathway for Killing Cancer Linked to Predictive Biomarker

Research presented at Cancer Immunology and Immunotherapy Conference EAGAN, MN — March 4, 2013 — Biothera has discovered a critical pathway by which Imprime PGG®, the company’s immunotherapeutic drug, binds to innate immune cells and directs them to attack and kill antibody-targeted cancer cells. The research was presented recently at the Cancer Immunology and Immunotherapy Conference as part of the Keystone Symposia held in Vancouver,...

Read More